Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection
暂无分享,去创建一个
J. McLellan | D. Wrapp | T. Fu | D. Freed | C. S. Nelson | S. Permar | M. Goodwin | Ningyan Zhang | Z. An | Jesse F. Mangold | Dai Wang | Sarah M Valencia | Joshua J. Tu | H. Webster | Jennifer A. Jenks | Hsuan-Yuan Wang
[1] D. Bernstein,et al. Antibody binding to native cytomegalovirus glycoprotein B predicts vaccine efficacy , 2020 .
[2] D. Bernstein,et al. 2651. Protection Against Human Cytomegalovirus Acquisition Is Associated with IgG Binding to Cell-Associated CMV glycoprotein B in Two Historical gB/MF59 Vaccine Cohorts , 2019, Open Forum Infectious Diseases.
[3] K. Koelle,et al. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees , 2018, Journal of Virology.
[4] G. Bi,et al. Different functional states of fusion protein gB revealed on human cytomegalovirus by cryo electron tomography with Volta phase plate , 2018, PLoS pathogens.
[5] L. Kauvar,et al. A Native Human Monoclonal Antibody Targeting HCMV gB (AD-2 Site I) , 2018, International journal of molecular sciences.
[6] C. S. Nelson,et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions , 2018, Proceedings of the National Academy of Sciences.
[7] P. Griffiths,et al. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies , 2018, Proceedings of the National Academy of Sciences.
[8] P. Griffiths,et al. Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia , 2018, The Journal of infectious diseases.
[9] W. Britt,et al. Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus , 2017, PLoS pathogens.
[10] Amy S. Espeseth,et al. Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection , 2017, Oncotarget.
[11] L. Kauvar,et al. Maternal Antibody Responses and Nonprimary Congenital Cytomegalovirus Infection of HIV-1-Exposed Infants. , 2016, The Journal of infectious diseases.
[12] M. Lanaspa,et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms , 2016, Nature Reviews Nephrology.
[13] A. Loundou,et al. Antibody-Dependent NK Cell Activation Is Associated with Late Kidney Allograft Dysfunction and the Complement-Independent Alloreactive Potential of Donor-Specific Antibodies , 2016, Front. Immunol..
[14] S. Permar,et al. The March towards a Vaccine for Congenital CMV: Rationale and Models , 2016, PLoS pathogens.
[15] D. Bernstein,et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial. , 2016, Vaccine.
[16] E. Heldwein,et al. Crystal Structure of the Human Cytomegalovirus Glycoprotein B , 2015, PLoS pathogens.
[17] A. Muntasell,et al. Antibody-Mediated Response of NKG2Cbright NK Cells against Human Cytomegalovirus , 2015, The Journal of Immunology.
[18] L. Kauvar,et al. A High-Affinity Native Human Antibody Neutralizes Human Cytomegalovirus Infection of Diverse Cell Types , 2014, Antimicrobial Agents and Chemotherapy.
[19] S. Boppana,et al. Congenital cytomegalovirus infection: clinical outcome. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] M. Franti,et al. Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. , 2013, Virology.
[21] T. Mertens,et al. Human Cytomegalovirus-Induced NKG2Chi CD57hi Natural Killer Cells Are Effectors Dependent on Humoral Antiviral Immunity , 2013, Journal of Virology.
[22] Sapna Sharma,et al. HCMV gB shares structural and functional properties with gB proteins from other herpesviruses. , 2013, Virology.
[23] V. Emery,et al. The “Silent” Global Burden of Congenital Cytomegalovirus , 2013, Clinical Microbiology Reviews.
[24] J. Arapović,et al. Innate immunity regulates adaptive immune response: lessons learned from studying the interplay between NK and CD8+ T cells during MCMV infection , 2012, Medical Microbiology and Immunology.
[25] T. Kepler,et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated , 2011, The Journal of experimental medicine.
[26] T. Winkler,et al. B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing Antibodies , 2011, PLoS pathogens.
[27] A. Davenport,et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial , 2011, The Lancet.
[28] C. Kotton. Management of cytomegalovirus infection in solid organ transplantation , 2010, Nature Reviews Nephrology.
[29] E. Puchhammer-Stöckl,et al. Human cytomegalovirus (HCMV) genotype populations in immunocompetent individuals during primary HCMV infection. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[30] Lawrence Corey,et al. Vaccine prevention of maternal cytomegalovirus infection. , 2009, The New England journal of medicine.
[31] K. Hashimoto,et al. Strain-specific seroepidemiology and reinfection of cytomegalovirus. , 2008, Microbes and infection.
[32] T. Kuijpers,et al. Human NK cells can control CMV infection in the absence of T cells. , 2008, Blood.
[33] J. Nelson,et al. Acceleration of allograft failure by cytomegalovirus. , 2007, Current opinion in immunology.
[34] M. Cannon,et al. Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection , 2007, Reviews in medical virology.
[35] S. Harrison,et al. Crystal Structure of Glycoprotein B from Herpes Simplex Virus 1 , 2006, Science.
[36] G. Weiner,et al. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. , 2005, Journal of immunological methods.
[37] Jessica M Malenfant,et al. CD107a as a functional marker for the identification of natural killer cell activity. , 2004, Journal of immunological methods.
[38] A. Varin,et al. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] R. Koup,et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.
[40] A. Tenório,et al. Different Cytomegalovirus Glycoprotein B Genotype Distribution in Serum and Cerebrospinal Fluid Specimens Determined by a Novel Multiplex Nested PCR , 2003, Journal of Clinical Microbiology.
[41] W. Britt,et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity , 2001, The New England journal of medicine.
[42] D. Glykofrydes,et al. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. , 1999, The Journal of general virology.
[43] M. Mach,et al. Strain-Specific Neutralization of Human Cytomegalovirus Isolates by Human Sera , 1999, Journal of Virology.
[44] W. Britt,et al. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. , 1995, The Journal of infectious diseases.
[45] M. Mach,et al. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. , 1992, The Journal of general virology.
[46] H. Friedman,et al. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. , 1985, Transplantation.
[47] D. Kaye. Clinical Infectious Diseases , 2017 .
[48] M. Manning,et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. , 1995, The Journal of infectious diseases.